Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. - Wikidata - wikimedia - TriplyDB

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

http://www.wikidata.org/entity/Q35005935

about

B-Raf specific antibody responses in melanoma patients Tumor cell recognition efficiency by T cells Authors' Reply Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor Loss of T Cell Antigen Recognition Arising from Changes in Peptide and Major Histocompatibility Complex Protein Flexibility: IMPLICATIONS FOR VACCINE DESIGN Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation.Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma Use of tumour-responsive T cells as cancer treatment.Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.Specific increase in potency via structure-based design of a TCR.Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes.Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.Specific roles of each TCR hemichain in generating functional chain-centric TCR.HPV-E7 delivered by engineered exosomes elicits a protective CD8⁺ T cell-mediated immune response Broadening the repertoire of melanoma-associated T-cell epitopes.microRNA-155, induced by interleukin-1ß, represses the expression of microphthalmia-associated transcription factor (MITF-M) in melanoma cells.Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.Immunohistochemistry in melanocytic proliferative lesions.Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles.Development of TLR9 agonists for cancer therapy New approaches in metastatic melanoma: biological and molecular targeted therapies.Novel antibodies as anticancer agents.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses.Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer.Behavior of immune players in the tumor microenvironment.Feasibility of immunotherapy for lymphangioleiomyomatosis.T-cell-receptor-like antibodies - generation, function and applications.Molecular insights for optimizing T cell receptor specificity against cancer.Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.Tracking antigen-specific CD8⁺ T cells using MHC class I multimers.

P2860

Q24794587-CAA884BB-23EB-4EEE-8D60-01D18EF9AB4A Q24805449-941397B3-F8ED-421A-9B95-ECF818B00B1C Q24805683-F2A68A5B-8C80-4962-BEB9-B873B0135D81 Q24814910-EA10F06D-2053-4644-8952-942032038579 Q26774669-564A14FA-D96E-457F-B74A-CD3A524D2559 Q27647534-6F46B150-A726-4112-98B9-EBB0DDC5A02B Q27656470-E4E4E2DE-8416-47B5-BDFE-E9034C5F6BB5 Q27674375-B3A8C128-E6D8-4B49-BC5B-8878B10879A7 Q33211563-E1DD32C9-B662-4755-AA65-3D815236E225 Q33671654-8C171D36-24E9-40BE-8565-DDAB8D11FB24 Q33734547-281141B8-2E90-434C-BC99-7461BC6A1CA5 Q34005128-536240B6-8034-4EB8-8113-5B724157CD96 Q34111789-C40FD9B7-F5BA-481A-8E4E-C7AEB347C84D Q34285656-C7C770CC-1A9C-44CE-A60F-F5DDAEECDE06 Q34338725-FA90A407-CD3F-45FC-9950-3ECD9BEC58FC Q34383054-F04B5A33-1DFE-41E0-87EC-9C2EDD3FA1A0 Q34594769-E68D2321-4883-4A7A-8D93-5DCA09953EF5 Q34669336-97491DEA-C2A0-4FDF-9F13-590BB66CB136 Q34953926-77E21F71-C7EF-4CDD-AD4A-DF821B875A87 Q35044333-49ACCBF9-25EB-40BF-A1B7-25C0FE1324B0 Q35205495-45D3F520-0008-4611-9FCF-1AD12FDF6DAD Q35232797-1F5A84DC-4268-4BED-A983-911A34D3F0BC Q35546276-E4E006EF-124A-4C7F-8CA1-CFDD34B44673 Q35597356-3E84A8DD-87B8-43E5-B031-8CE109DF15AD Q35653886-DE2FA3D8-3F24-418C-B77E-2F1E19115262 Q35798186-8CD14930-2292-4223-A371-3D2B034A0249 Q36286948-177AC9B3-2067-4959-A76B-E5EE63CB02C1 Q36471831-DA148EA0-DBA8-4B9B-8A8C-78089CEC5E00 Q36809776-E7981420-F9AF-4DE7-9F03-14D8C7CB6509 Q36817127-F7E251C9-579D-4ED0-89E9-48400F2416B5 Q36832141-0CEC1BD1-8D91-447F-A8AA-390567EDB7BB Q37098840-71525BAB-10CB-4C21-8EC8-A19AC583AD15 Q37114832-F66A7E58-D3FE-4A08-B0DA-8863A924D189 Q37293938-913668B4-9B71-4683-B96C-EE859374F866 Q37362981-47F60C69-4BEA-4B47-AE1A-0A5C1CBD880A Q37462607-B80A3BCF-BC83-466C-B809-19B2FBA0D4A1 Q37987723-378480BC-490C-46E4-8212-4CD045C8E85E Q38117139-5FEA3A27-53D1-478E-8D98-F2BA05DF7422 Q38816516-A94B4F28-0D5F-4034-BAAD-8E42C4509FC8 Q39483297-3EB64FEB-68B0-4B21-AFA2-947E5A6A5C81

P2860

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

http://www.wikidata.org/entity/Q35005935

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@ast

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@en

type

label

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@ast

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@en

prefLabel

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@ast

Antigenicity and immunogenicit ...... eactive CTL in human melanoma.

@en

P1433

Q35005935-8FFB4578-9F27-45A8-931A-C6AF18AC609D

P1476

Q35005935-80F5C118-DC41-418B-8CB7-17AAF0E794FF

P2093

Q35005935-08DBE800-4A3B-4E02-AF38-513DE20C817C

Q35005935-1D815CC5-6099-4D15-896E-B7DE1EC75AF7

Q35005935-2129B055-61ED-4B52-A6D6-B4AAF028B7F4

Q35005935-32E458E4-6BC0-4FC7-B521-5512140C8E78

Q35005935-356CE5F7-0E2B-4DA9-B5AB-47F9B31DB7B8

Q35005935-44F6B927-C421-41B4-B65A-83B98625D1AC

Q35005935-48CB8E11-F28C-4A9F-BA00-AAD9E980B417

Q35005935-4FF06E37-C1BD-4535-AFC0-82324A5CE428

Q35005935-747AAE26-7AEE-4E9D-A48F-8FFE36F984CA

Q35005935-74DEA49A-30D2-40CB-A618-21BAE329B18C

P2860

Q35005935-04C44C3D-37A7-4680-8944-EA8959D94324

Q35005935-0D081545-B0D6-4BD2-A4A6-78732FF3D2BF

Q35005935-10BF0CE7-D9B9-4569-B255-484210DC5DDF

Q35005935-1721E61C-1D10-4C1B-B1C5-F16437EA41AA

Q35005935-25631F56-27BA-45AA-B3F6-517178FA24D6

Q35005935-29285D79-C6A3-4035-9A97-321BA95D9E51

Q35005935-330BD4D5-7D32-491F-81A2-C046ED26CC77

Q35005935-3777B4A2-9869-48D3-9977-D3BC70497A78

Q35005935-3BB66812-3B0E-4CA3-AC09-05031A8F1733

Q35005935-43954288-D489-4A76-97AC-0BAA078E17FA

P304

Q35005935-FD37F19E-6316-49D3-87E8-A7C3AF1453C1

P31

Q35005935-70B1A98E-530E-4E55-A425-0B30BAD910AD

P356

Q35005935-D5833898-1A6D-4772-A18F-9A6DB13AA60F

P478

Q35005935-E94ABB73-2808-4DF5-9101-933C2F9BF39F

P50

Q35005935-05D3FF1C-54EA-4D0A-A76F-6F63CFD78753

P577

Q35005935-8418243E-9D1D-41E5-BBEC-1BFF084F8CBF

P698

Q35005935-B2A7A4AB-5776-4574-A56A-13118F0C9C81

P356

J.1600-065X.2002.18808.X

P1433

Immunological Reviews

P1476

Antigenicity and immunogenicit ...... reactive CTL in human melanoma

@en

P2093

Alfred Zippelius

http://www.w3.org/2001/XMLSchema#string

Daniel E Speiser

http://www.w3.org/2001/XMLSchema#string

Danielle Liénard

http://www.w3.org/2001/XMLSchema#string

Danila Valmori

http://www.w3.org/2001/XMLSchema#string

Donata Rimoldi

http://www.w3.org/2001/XMLSchema#string

Ferdy Lejeune

http://www.w3.org/2001/XMLSchema#string

Frederic Lévy

http://www.w3.org/2001/XMLSchema#string

Immanuel F Luescher

http://www.w3.org/2001/XMLSchema#string

Jean-Charles Cerottini

http://www.w3.org/2001/XMLSchema#string

Mikael J Pittet

http://www.w3.org/2001/XMLSchema#string

P2860

The melanocytic protein Melan-A/MART-1 has a subcellular localization distinct from typical melanosomal proteins

Estimating the precursor frequency of naive antigen-specific CD8 T cells

Thymic selection generates a large T cell pool recognizing a self-peptide in humans

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site

Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes

Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Phenotypic analysis of antigen-specific T lymphocytes

Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100.

P304

81-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1034/J.1600-065X.2002.18808.X

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12445283

http://www.w3.org/2001/XMLSchema#string